DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.11
-0.03 (-1.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.47
Open2.05
Bid2.11 x 400
Ask2.12 x 1300
Day's Range2.04 - 2.19
52 Week Range0.74 - 2.55
Volume866,181
Avg. Volume931,039
Market Cap323.541M
Beta2.31
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.37
Trade prices are not sourced from all markets
  • PR Newswire23 days ago

    DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis

    CUPERTINO, Calif., March 29, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of alcoholic hepatitis (AH) on Thursday, April 5 at 11:00 a.m. Eastern Time. The call will feature a presentation by KOL Paul Kwo, MD, who will present an overview of alcoholic hepatitis, including an overview of the disease and its progression, current treatment options and new treatments in development for alcoholic hepatitis.  Dr. Kwo will be available to answer questions at the conclusion of the call. DURECT's management team will also provide an overview of the Company's ongoing clinical development program for DUR-928, including a summary of preclinical and clinical data disclosed to-date and a review of the Company's Phase 2 study in patients with alcoholic hepatitis.  DUR-928 is the lead product candidate in DURECT's Epigenetic Regulator Program.  It is an endogenous, first-in-class small molecule that has been shown in nonclinical studies to modulate the activity of nuclear receptors playing an important regulatory role in lipid homeostasis, inflammation, and cell survival.

  • GlobeNewswire26 days ago

    Investor Expectations to Drive Momentum within Aon plc, Endeavour Silver, BlackBerry, DURECT, Castle Brands, and Nabors Industries — Discovering Underlying Factors of Influence

    NEW YORK, March 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • PR Newswirelast month

    DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER

    CUPERTINO, Calif. , March 20, 2018 /PRNewswire/ --   DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug ...

  • Is DURECT Corporation (NASDAQ:DRRX) Undervalued?
    Simply Wall St.last month

    Is DURECT Corporation (NASDAQ:DRRX) Undervalued?

    DURECT Corporation (NASDAQ:DRRX), a pharmaceuticals company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a small capRead More...

  • Benzinga2 months ago

    Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors

    DURECT Corporation (NASDAQ: DRRX ) has had a rough few months since the failure of a Phase 3 trial for its formerly leading drug candidate. Days after reporting top- and bottom-line quarterly beats, the ...

  • Associated Press2 months ago

    Durect tops 4Q revenue forecasts

    On a per-share basis, the Cupertino, California-based company said it had net income of 5 cents. The specialty pharmaceutical company posted revenue of $19.5 million in the period, which topped Street ...

  • PR Newswire2 months ago

    DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs

    Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ...

  • PR Newswire2 months ago

    DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)

    CUPERTINO, Calif., Feb. 26, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with primary sclerosing cholangitis (PSC).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in several hepatic and renal diseases such as nonalcoholic steatohepatitis (NASH) and other disorders of the liver such as PSC, in acute organ injuries such as acute liver and kidney injury, and in inflammatory skin disorders such as psoriasis and atopic dermatitis. "There is a clear unmet medical need to find effective medical therapy in PSC and prevent progression to end stage liver disease, so we look forward to seeing how these patients respond when treated with this orally administered endogenous small molecule," stated Dr. Kidist K. Yimam, Medical Director, Autoimmune Liver Disease Program at California Pacific Medical Center, Department of Hepatology and Liver Transplantation, San Francisco, CA.  This is one of 15 sites planned for this study and the first site to enroll a patient.

  • PR Newswire2 months ago

    DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call

    CUPERTINO, Calif., Feb. 22, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (DRRX) fourth quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast of the presentation will be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

  • PR Newswire2 months ago

    DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)

    CUPERTINO, Calif., Feb. 20, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time. The call will feature a presentation by KOL Keith Lindor, MD, who will present an overview of primary sclerosing cholangitis, including an overview of the disease and its progression, current treatment options and the treatment landscape for PSC.  He will be available to answer questions at the conclusion of the call. Dr. Keith Lindor is Senior Advisor to the Provost at Arizona State University (ASU) and a Professor of Medicine at Mayo Clinic.

  • PR Newswire2 months ago

    DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics

    CUPERTINO, Calif. , Feb. 14, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that it has resubmitted the New ...

  • PR Newswire4 months ago

    DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot

    CUPERTINO, Calif. , Dec. 13, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has accepted ...

  • ACCESSWIRE4 months ago

    DURECT Corporation: New Patent Revenue, Analysts Review, Earnings and Current Pipeline Progress

    NEW YORK, NY / ACCESSWIRE / December 12, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Capital Cube4 months ago

    ETFs with exposure to DURECT Corp. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to DURECT Corp. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube5 months ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of DURECT Corp. – Pain Therapeutics, Inc., Zogenix, Inc., Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, Heron Therapeutics Inc and Pacira Pharmaceuticals, Inc. (PTIE-US, ZGNX-US, JNJ-US, PFE-US, LLY-US, ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to DURECT Corp. : November 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT

    Q3 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Research6 months ago

    DRRX: Focus will be Shifted to DUR-928 Programs

    Revenue from R&D collaborations was $5.6 million in third quarter 2017, compared to $0.4 million in third quarter 2016. A large portion of that increase related to the recognition of deferred revenue from upfront fees already received by the company.

  • Associated Press6 months ago

    Durect tops Street 3Q forecasts

    On a per-share basis, the Cupertino, California-based company said it had net income of 4 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • PR Newswire6 months ago

    DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call

    CUPERTINO, Calif. , Oct. 26, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2017 financial results press release, you are invited to listen to a conference call ...

  • PR Newswire6 months ago

    DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint

    CUPERTINO, Calif., Oct. 19, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl.  While results trended in favor of POSIMIR versus the comparator, they did not achieve statistical significance.  POSIMIR is an investigational drug candidate being developed for the treatment of post-surgical pain.